Thermo Fisher Scientific has completed an expansion at its dry powder media manufacturing plant, expanding the site’s production arsenal to include technology and materials used in the development and commercial production of new vaccines and biologic drugs.
The $76 million outlay falls under the umbrella of Thermo Fisher’s $650 million bioprocessing investment unveiled last year. The entire project is designed to erect “flexible, scalable and reliable bioprocessing production capacity” for prophylactics and biologics, including COVID-19 vaccines.